Sermorelin is a synthetic peptide made of the first 29 amino acids of human growth hormone releasing hormone, and reference sources describe it as a subcutaneous injectable reconstituted from a lyophilized powder before use. Two dosing worlds get blurred in the record: the historical FDA-approved diagnostic test used a single intravenous microgram-per-kilogram dose to probe pituitary function, while the compounded reference context discussed today describes adult subcutaneous doses of roughly 100 to 500 micrograms, most often once daily at bedtime. None of this is FDA-approved for the anti-aging or wellness use it is now marketed for, and published frameworks treat the number as something a prescriber individualizes rather than a fixed universal amount.
Sermorelin dosing splits into an FDA-approved historical diagnostic protocol of one microgram per kilogram given intravenously and a non-approved compounded reference range of roughly 100 to 500 micrograms delivered subcutaneously once daily, and the two must never be read as one figure.
The reference literature carries two dosing contexts that should not be conflated. The historical diagnostic indication used a single intravenous dose of one microgram per kilogram of body weight to provoke and measure pituitary growth hormone output; the compounded adult context most discussed today cites subcutaneous amounts commonly between 100 and 500 micrograms per dose. Amounts are expressed in micrograms of peptide rather than international units, which sets them apart from recombinant growth hormone conventions.
| Dosing context | Amount cited | Route |
|---|---|---|
| Historical diagnostic (FDA-approved) | 1 mcg/kg, single dose | Intravenous |
| Compounded reference range | 100 to 500 mcg per dose | Subcutaneous |
| Frequently cited midpoint | 200 to 300 mcg once daily | Subcutaneous |
Compounded reference material commonly cites subcutaneous adult doses of 100 to 500 micrograms with 200 to 300 micrograms once daily as a frequently referenced midpoint, described as a titration starting point rather than a fixed prescription, while amounts above the cited upper range are noted to add little benefit and raise reaction risk.
For the compounded reference form, subcutaneous injection is the route the literature describes, since the peptide absorbs well from subcutaneous tissue and reaches its pituitary target without intravenous access, which is why sources note it as suited to at-home use under a prescriber's direction. This stands apart from the original FDA-approved diagnostic product, which was a single intravenous dose given in a clinical setting to test pituitary response rather than for ongoing self-administration.
The compounded reference form is documented as a subcutaneous injection using a small-gauge insulin-style syringe into rotated sites such as the abdomen, outer thigh, or upper arm, distinct from the original FDA-approved diagnostic product delivered as a single intravenous dose in a clinical setting.
Timing carries mechanistic weight in the reference material because sermorelin does not supply growth hormone directly; it signals the anterior pituitary to release the body's own stored hormone in a pulse. The largest natural pulse occurs during the early hours of deep sleep, which is why sources describe a bedtime dose as reinforcing that nocturnal surge rather than working against the body's rhythm. Because the peptide prompts an endogenous pulse instead of flooding the system with a constant external level, the somatostatin negative-feedback loop stays in place, cited as the reason the pulsatile approach is described as more physiologic than a steady exogenous dose.
Because sermorelin triggers an endogenous growth hormone pulse rather than delivering the hormone directly, reference sources describe bedtime administration on an empty stomach as the way to align the induced pulse with the body's largest natural nocturnal surge and avoid the blunting effect of a carbohydrate- or fat-heavy meal.
Sermorelin arrives as a lyophilized powder that the record describes as requiring reconstitution before injection, and the handling detail matters because heat, light, and freeze-thaw cycles degrade peptide potency. What the compounding pharmacy specifies governs any individual case; the steps below are how the published reference guidance describes the process.
Published reference guidance describes reconstituting sermorelin by adding sterile diluent slowly down the vial wall and swirling gently, then storing the solution refrigerated at two to eight degrees Celsius away from light and freezing, with a cited shelf life often on the order of several weeks before the remainder is discarded.
Individualization sits at the center of how reference frameworks describe sermorelin dosing, because the peptide's effect depends on each person's own pituitary responsiveness, which shifts with age and baseline endocrine status. The recurring theme in the literature is that the number is a moving target a prescriber sets against measured and reported response over weeks, not a static prescription.
Reference frameworks describe sermorelin dosing as individualized by a prescriber against age, endocrine status, body composition, tolerability, and serial serum IGF-1 measurements kept within an age-appropriate band, treating the dose as a titrated moving target rather than a fixed prescription.
In its formally approved historical role, sermorelin was a diagnostic agent rather than a long-term therapy, and the record shows its dose calculated strictly by body weight: one microgram per kilogram given as a single intravenous injection, typically in the morning after an overnight fast. The purpose was provocative testing, meaning the dose was meant to trigger a measurable burst of growth hormone so clinicians could judge whether the gland could respond, not to sustain any ongoing hormonal effect.
In its FDA-approved diagnostic role, sermorelin was dosed strictly by body weight at one microgram per kilogram as a single morning intravenous injection after an overnight fast, with timed blood draws over the next hour capturing the peak growth hormone response, a weight-based single-dose logic that stands apart from the fixed-microgram repeated subcutaneous pattern of later compounded reference use.
Reference discussions of sermorelin handling return to a cluster of avoidable mistakes, and the reason each one matters is potency, sterility, or a blunted effect. The published record frames these as documented pitfalls, not personal instruction; a prescriber and pharmacist provide the authoritative directions for any individual.
The reference literature identifies forceful reconstitution, room-temperature or light or freeze exposure, dosing near a fatty or carbohydrate-heavy meal, and injection lapses such as reused needles or unrotated shallow injections as avoidable errors that degrade potency, blunt the growth hormone response, or raise contamination and site-reaction risk.
The core distinction in the reference record is that sermorelin doses a signal, not the hormone itself. A direct growth hormone preparation delivers the finished hormone into the bloodstream, so its dose is calibrated to a target circulating level and conventionally expressed in international units; sermorelin instead supplies a releasing-hormone analog that asks the pituitary to secrete its own hormone, so amounts are expressed in micrograms of peptide and calibrated to provoke a pulse. Recognizing which model a dosing figure belongs to is what makes the figure readable.
| Criteria | Direct growth hormone | Sermorelin |
|---|---|---|
| What is dosed | The finished hormone | A releasing-hormone signal |
| Dose target | A steady circulating level | An endogenous pulse |
| Unit convention | International units | Micrograms of peptide |
| Feedback ceiling | None built in | Somatostatin loop retained |
| Typical route | Once-daily subcutaneous | Once-daily subcutaneous |
Direct growth hormone preparations deliver the finished hormone dosed in international units toward a steady circulating level, while sermorelin supplies a releasing-hormone analog dosed in micrograms of peptide to provoke a pituitary pulse, leaving the somatostatin negative-feedback loop as a built-in ceiling that direct administration lacks.
Educational use only. This article describes what the published scientific and clinical literature reports about Sermorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
